Aetna plans exclude coverage of cosmetic surgery that is not medically necessary, but generally provide coverage when the surgery is needed to improve the functioning of a body part or otherwise medically necessary even if the surgery also improves or changes the appearance of a portion of the body. Additionally, many Aetna plans specify that certain procedures are not considered to be cosmetic surgery (e.g., surgery to correct the result of injury, post-mastectomy breast reconstruction, surgery needed to treat certain congenital defects such as cleft lip or cleft palate). Please check benefit plan descriptions for details.
This policy statement supplements plan coverage language by identifying procedures that Aetna considers medically necessary despite cosmetic aspects, and other cosmetic procedures that Aetna considers not medically necessary. Please note that, while this policy statement addresses many common procedures, it does not address all procedures that might be considered to be cosmetic surgery excluded from coverage. Aetna reserves the right to deny coverage for other procedures that are cosmetic and not medically necessary.
The following procedures are considered cosmetic in nature:
The following procedures are considered medically necessary when criteria are met. The requesting physicians may be required to submit documentation, including photographs, letters documenting medical necessity, chart records, etc.
Dermal injections of FDA-approved fillers (e.g., poly-L-lactic acid dermal injection (Sculptra) or calcium hydroxylapatite dermal injection (Radiesse)) for HIV lipoatrophy: Considered medically necessary for treating facial lipodystrophy syndrome due to antiretroviral therapy in HIV-infected persons; considered cosmetic for all other indications. Retreatments with FDA-approved fillers are considered medically necessary for facial lipodystrophy syndrome due to antiretroviral therapy in HIV-infected persons.
Earlobe repair: Repair (e.g., tear) of a traumatic injury is considered medically necessary. Earlobe repair to close a stretched pierce hole, in the absence of a traumatic injury, is considered cosmetic.
Excision or shaving of rhinophyma for the treatment of bleeding or infection refractory to medical therapy (i.e. the need for repeated cautery of bleeding telangiectasias or frequent courses of antibiotics for pustular eruptions). Excision or shaving of rhinophyma is considered cosmetic when the afore-mentioned criteria are not met.
Keloids: Repair of keloids is considered medically necessary if they cause pain or a functional limitation. Note: For repair of keloids that do not cause pain or functional impairment, exceptions to cosmetic surgery exclusion may apply. Please check benefit plan descriptions. See also CPB 0551 - Radiation Treatment of Keloids.
Lipomas: Excision is considered medically necessary if lipomas are tender and inhibit the member's ability to perform daily activities due to the lipomas' location on body parts that are subject to regular touch or pressure.
Otoplasty/Pinnaplasty: Considered medically necessary when performed to improve hearing by directing sound in the ear canal, whether the ears are absent or deformed from trauma, surgery, disease, or congenital defect. Otoplasty to correct large or protruding ears (bat ears) is considered cosmetic when the surgery will not improve hearing.
Pulsed-dye laser treatment and excision of port wine stains and other hemangiomas: Considered medically necessary when lesions are located on the face and neck. Also, removal of symptomatic scrotal hemangiomas and symptomatic cavernous hemangiomas is considered medically necessary. See also CPB 0559 - Pulsed Dye Laser Treatment.
Rhytidectomy (including meloplasty, face lift): Considered medically necessary when there is functional impairment that cannot be corrected without surgery.
Scar revision: Repair of scars that result from surgery is considered medically necessary if they cause symptoms or functional impairment. Note: Exceptions to cosmetic surgery exclusion may apply to repair of scars that do not cause pain or functional impairment. Please check benefit plan descriptions.
Note: Most Aetna plans cover prosthetic devices that temporarily or permanently replace all or part of an external body part that is lost or impaired as a result of disease, injury or congenital defect. The surgical implantation or attachment of covered prosthetics is covered, regardless of whether the covered prosthetic is functional (i.e., regardless of whether the prosthetic improves or restores a bodily function). The following surgical implantations are covered when medical necessity criteria for the prosthetic device are met, even though the prosthetic device does not correct a functional deficit.
The following prostheses are considered medically necessary when criteria are met:
Hair transplant: Considered medically necessary when performed to correct permanent hair loss that is clearly caused by disease or injury. Hair transplants performed to correct male pattern baldness or age-related hair thinning in women are considered cosmetic
Testicular prostheses: Considered medically necessary for replacement of congenitally absent testes, or testes lost due to disease, injury, or surgery.
See also the following CPBs that address other procedures that may be considered cosmetic:
Mest and Humble (2009) evaluated the long-term safety, duration of effect, and satisfaction with serial injections of poly-l-lactic acid (PLLA) for HIV-associated facial lipoatrophy. In this single-site, open-label, re-treatment study, 65 HIV-positive patients were treated with injectable PLLA every 5 weeks (until optimal re-correction). Presenting degree of lipoatrophy based on the James scale (1 = mild, 4 = severe) was reviewed. Skin thickness was measured at fixed points with calipers. Patients completed a post-retreatment satisfaction questionnaire. Nearly 10 % of patients had persistent correction greater than 36 months, based on patient report. Approximately 50 % required 3 or fewer re-treatments to maintain satisfactory correction (determined by patient and physician). Milder facial lipoatrophy (james scale score 1 to 2) on initial presentation required fewer re-treatments and had more sustained correction. Time to first re-treatment varied according to James scale score: 1 (21.4 months) and 4 (13.0 months). The majority of patients required or asked for 4 re-treatments or less over a 24-month period. The mean patient satisfaction score was 4.9 (1 = dissatisfied, 5 = very satisfied) at study end. No serious adverse events were reported. The authors concluded that injectable PLLA is a safe and effective long-term treatment option for HIV-associated lipoatrophy.
The cosmetic surgery exclusion precludes payment for any surgical procedure directed at improving appearance. The condition giving rise to the patient's pre-operative appearance is generally not a consideration. The only exception to the exclusion is surgery for the prompt repair of an accidental injury or for the improvement of a malformed body member which coincidentally serves some cosmetic purpose. Since surgery to correct a condition of "moon face" which developed as a side effect of cortisone therapy does not meet the exception to the exclusion, it is not covered under Medicare (§1862(a)(10) of the Act).
An UpToDate review on “Overview of breast disorders in children and adolescents” (Banikarim and De Silva, 2012) states that “Tuberous breast is a variant of breast development in which the base of the breast is limited and the nipple and areola are overdeveloped. The etiology is unknown. If the breast examination is otherwise normal, the patient may be referred for cosmetic surgery. The available surgical options vary depending on the location of the hypoplastic breast tissue …. Teenagers may seek breast augmentation for reconstructive purposes related to congenital defects (e.g., amastia, severe breast asymmetry, tuberous breast) or for purely aesthetic reasons”.
CPT Codes / HCPCS Codes / ICD-9 Codes
CPT codes covered if selection criteria are met:
11300 - 11313
11920 - 11922
11950 - 11954
15220 - 15221
15780 - 15782
15788 - 15793
15820 - 15823
15840 - 15845
17106 - 17108
19318 - 19350, 19357 - 19396
21740 - 21743
30420, 30435, 30450, 30460, 30462
67901 - 67909
CPT codes not covered for indications listed in the CPB:
15775 - 15776
15786 - 15787
15824 - 15829
15832 - 15839
15876 - 15879
21120 - 21123
21125 - 21127
21137 - 21139
30400 - 30410
49560 - 49561
49565 - 49566
HCPCS codes covered if selection criteria are met:
Dermal injection procedure(s) for facial lipodystrohy syndrome (LDS) and provision of Radiesse or Sculptra dermal filler, including all items and supplies
Synthetic graft - mandible or facial bones, by report
Dermal filler injection(s) for the treatment of facial lipodystrophy syndrome (LDS) (e.g., as a result of highly active antiretroviral therapy)
BlueCross BlueShield of Pennsylvania, Xact Medicare Services. Cosmetic surgery vs. reconstructive surgery. Medicare Medical Policy Bulletin No. S-28F. Camp Hill, PA: Xact Medicare Services; November 24, 1997. Available at: http://www.hgsa.com/professionals/policy/s28.html. Accessed November 16, 2001.
Kwon SD, Kye YC. Treatment of scars with a pulsed Er:YAG laser. J Cutan Laser Ther. 2000;2(1):27-31.
Tanzi EL, Alster TS. Treatment of atrophic facial acne scars with a dual-mode Er:YAG laser. Dermatol Surg. 2002;28(7):551-555.
Alster T. Laser scar revision: Comparison study of 585-nm pulsed dye laser with and without intralesional corticosteroids. Dermatol Surg. 2003;29(1):25-29.
Papadavid E, Katsambas A. Lasers for facial rejuvenation: A review. Int J Dermatol. 2003;42(6):480-487.
Cooter R, Babidge W. Ultrasound-assisted lipoplasty. North Adelaide, South Australia: Australian Safety and Efficacy Register of New Interventional Procedures - Surgical (ASERNIP-S); 1999.
Medical Services Advisory Committee (MSAC). Total ear reconstruction. Canberra, Australia: Medical Services Advisory Committee; 2000.
State of Minnesota, Health Technology Advisory Committee (HTAC). Tumescent liposuction. St. Paul, MN: HTAC; 2002.
Fischbacher C. Cosmetic breast augmentation. Bazian Ltd., eds. London, UK: Wessex Institute for Health Research and Development, University of Southampton; 2003.
Ball CM. Laser treatment of unwanted hair. Bazian Ltd., eds. London, UK: Wessex Institute for Health Research and Development, University of Southampton; 2003.
Patterson J. Outcomes of abdominoplasty. Bazian Ltd., eds. London, UK: Wessex Institute for Health Research and Development, University of Southampton; 2003.
Lafaurie M, Dolivo M, Porcher R, et al. Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients. J Acquir Immune Defic Syndr. 2005;38(4):393-398.
Beljaards RC, de Roos KP, Bruins FG. NewFill for skin augmentation: A new filler or failure? Dermatol Surg. 2005;31(7 Pt 1):772-776; discussion 776.
American College of Obstetricians and Gynecologists (ACOG). Vaginal 'rejuvenation' and cosmetic vaginal procedures. ACOG Committee Opinion No. 378. Washington, DC: ACOG; September 2007.
Vedamurthy M. Mesotherapy. Indian J Dermatol Venereol Leprol. 2007;73(1):60-62.
Rastogi R. Diffuse cavernous hemangioma of the penis, scrotum, perineum, and rectum -- a rare tumor. Saudi J Kidney Dis Transpl. 2008;19(4):614-618.
Atiyeh BS, Ibrahim AE, Dibo SA. Cosmetic mesotherapy: Between scientific evidence, science fiction, and lucrative business. Aesthetic Plast Surg. 2008;32(6):842-849.
Park SH, Kim DW, Lee MA, et al. Effectiveness of mesotherapy on body contouring. Plast Reconstr Surg. 2008;121(4):179e-185e.
Ergün O, Ceylan BG, Armagan A, et al. A giant scrotal cavernous hemangioma extending to the penis and perineum: A case report. Kaohsiung J Med Sci. 2009;25(10):559-561.
Centers for Medicare & Medicaid Services (CMS). Decision memo for dermal injections for the treatment of facial lipodystrophy syndrome (FLS) (CAG-00412N). Medicare Coverage Database. Baltimore, MD: CMS; March 23, 2010.
Mest DR, Humble GM. Retreatment with injectable poly-l-lactic acid for HIV-associated facial lipoatrophy: 24-month extension of the Blue Pacific study. Dermatol Surg. 2009;35 Suppl 1:350-359.
Banikarim C, De Silva NK. Overview of breast disorders in children and adolescents. Last reviewed November 2012. UpToDate Inc. Waltham, MA.
Copyright Aetna Inc. All rights reserved. Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.